Equities research analysts expect Sonendo, Inc. (NYSE:SONX – Get Rating) to announce $9.74 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Sonendo’s earnings, with the highest sales estimate coming in at $9.98 million and the lowest estimate coming in at $9.50 million. The company is scheduled to report its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Sonendo will report full year sales of $41.80 million for the current financial year, with estimates ranging from $41.20 million to $42.40 million. For the next fiscal year, analysts expect that the company will report sales of $57.72 million, with estimates ranging from $57.30 million to $58.13 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that follow Sonendo.
Sonendo (NYSE:SONX – Get Rating) last posted its earnings results on Tuesday, May 10th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.02).
Shares of SONX traded up $0.04 during trading hours on Friday, hitting $2.60. The stock had a trading volume of 161,525 shares, compared to its average volume of 130,779. The company’s fifty day moving average is $3.61 and its two-hundred day moving average is $6.13. The company has a quick ratio of 6.19, a current ratio of 6.86 and a debt-to-equity ratio of 0.46. Sonendo has a 52 week low of $2.50 and a 52 week high of $12.24.
A number of institutional investors have recently added to or reduced their stakes in SONX. Bank of America Corp DE acquired a new position in Sonendo during the 4th quarter valued at about $31,000. Wealthsource Partners LLC acquired a new position in Sonendo during the 1st quarter valued at about $40,000. Northern Trust Corp acquired a new position in Sonendo during the 4th quarter valued at about $76,000. Cubist Systematic Strategies LLC acquired a new position in Sonendo during the 4th quarter valued at about $82,000. Finally, Point72 Asset Management L.P. acquired a new position in Sonendo during the 4th quarter valued at about $115,000. Institutional investors own 80.42% of the company’s stock.
Sonendo Company Profile (Get Rating)
Sonendo, Inc, a commercial-stage medical technology company, develops, manufactures, and commercializes devices for root canal therapy in the United States and Canada. It provides GentleWave, a tooth decay treatment device for cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure.
- Get a free copy of the StockNews.com research report on Sonendo (SONX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sonendo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonendo and related companies with MarketBeat.com's FREE daily email newsletter.